

AstraZeneca Hits U.K. Antitrust Review with \$39B Alexion Buy After U.S. FTC Clearance

May 25, 2021

ATTORNEYS

Maier, Jeny

Angus Liu
FiercePharma

PRACTICE AREAS

Antitrust

Axinn partner Jeny Maier's commentary was included in the *FiercePharma* article, "AstraZeneca Hits U.K. Antitrust Review with \$39B Alexion Buy After U.S. FTC Clearance."

[Click here to access the article.](#)